Severe ICANS is associated with cytopenia, coagulopathy, and increased inflammation. (A) The baseline (just before starting lymphodepletion chemotherapy) and posttreatment levels of white blood cell count, hemoglobin, and platelet count were comparable between patients with and without severe ICANS. Anemia, thrombocytopenia, and increased transfusion burden were associated in patients with severe ICANS. (B) The baseline CRP and ferritin were similar between the 2 groups. The peak CRP level peaked higher in patients with severe ICANS. (C) The baseline fibrinogen level was similar between the 2 groups. The fibrinogen level nadir was lower in patients with severe ICANS. (D) The cumulative dose of tocilizumab, steroid (equivalent dose of dexamethasone), and anakinra were compared between patients with and without severe ICANS. The tocilizumab total cumulative dose is similar between the 2 groups, and mainly used before ICANS onset. Patients with severe ICANS received more cumulative doses of steroid, mainly given after the onset of ICANS, and received higher cumulative doses of anakinra. ∗P < .05, ∗∗P < .01, and ∗∗∗P < .001; by Wilcox rank sum test (continuous) or Fisher exact test (categorical).